Journal of cardiology最新文献

{"title":"Nanoparticle-driven drug delivery system for cardiovascular treatment.","authors":"Raj Patel, Dhruvi Patel, Unnati Dani, Ketan Kuperkar","doi":"10.1016/j.jjcc.2025.06.004","DOIUrl":"10.1016/j.jjcc.2025.06.004","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) is the world's major concern affecting the heart, blood arteries, and the blood that flows through and between them, making it a significant obstacle to contemporary healthcare practices. Approximately one in three individuals has a CVD, and many of them have several, overlapping diseases that might eventually result in catastrophic events such as a heart attack or stroke. The previous century opened the door for progress of life-saving drugs and treatment modalities. Recent developments in nanomaterials provide novel approaches for the treatment of CVD. Due to their unique properties, which include increased target specificity, sensitivity, and both active and passive targeting of cardiac tissues, the use of nanoparticles as carriers has received a lot of attention in the field of cardiology. Drug delivery using heart-targeted nanocarriers is a safe, efficient method of treating heart-related conditions such as hypertension, atherosclerosis, and myocardial infarction. Here, we highlight significant clinical opportunities in the quickly emerging field of CVD nanomedicine. This review concentrates on the use of nanoparticle-based therapeutics in CVD and provides a key take away regarding the use of metal, lipid, and polymer-based nanoparticle in CVD treatment. In this review, we emphasize recent advances in the use of nanomedicine to treat CVD and the therapeutic potential of drug delivery via nanoparticles in clinical prospects.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNF213 and cardiovascular disease: A review of histopathological, genetic perspectives, and potential molecular mechanisms.","authors":"Toshinaru Kawakami, Masamichi Ito, Takayuki Isagawa, Takahiro Kuchimaru, Norihiko Takeda","doi":"10.1016/j.jjcc.2025.06.001","DOIUrl":"10.1016/j.jjcc.2025.06.001","url":null,"abstract":"<p><p>The ring finger protein 213 (RNF213) gene, identified in 2011 as a susceptibility gene for moyamoya disease (MMD), has since been recognized as a key factor in a broader spectrum of vascular disorders. The p.R4810K mutation in RNF213 is particularly common among Japanese MMD patients, although a smaller percentage of healthy individuals also carry the mutation, indicating that environmental factors, alongside genetic predisposition, likely influence disease onset. RNF213, a large E3 ubiquitin ligase, plays essential roles in vascular homeostasis, immune response, and endoplasmic reticulum stress reaction. Its mutation disrupts normal angiogenesis, contributing to abnormal vascular remodeling in conditions such as pulmonary hypertension and coronary artery disease. This review examines the multifaceted role of RNF213 and its p.R4810K mutation in the pathogenesis of MMD and other vascular conditions, collectively referred to as RNF213-associated vascular diseases. While research has begun to clarify the mutation's effects on angiogenesis and the involved pathways, the roles of RNF213 and its mutation in vascular integrity remain unclear. This comprehensive overview underscores the complex interaction between genetic and environmental factors in RNF213-related vascular diseases and calls for further research to elucidate these mechanisms and develop targeted therapeutic interventions.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of left ventricular volumes and ejection fraction using high-intensity echo band as a landmark: Comparison between two-dimensional echocardiography and cardiac magnetic resonance imaging.","authors":"Takaya Higuchi, Yasuyuki Chiba, Nobuaki Yoshino, Kenichi Matsubara, Mashiro Taniguchi, Yuki Ogino, Toshihiro Shimizu, Toshihisa Anzai","doi":"10.1016/j.jjcc.2025.05.017","DOIUrl":"10.1016/j.jjcc.2025.05.017","url":null,"abstract":"<p><strong>Background: </strong>The trace line for left ventricular (LV) volumes and ejection fraction (EF) measurements in 2-dimensional echocardiography (2DE) are often based on the empirical judgment of the examiner. We evaluated whether trace lines along the inner side of the high-intensity echo band that characterized LV endocardial boundary is useful for accurate measurements, with cardiac magnetic resonance (CMR) imaging as reference.</p><p><strong>Methods: </strong>We compared the accuracy of LV volumes [end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV)] and EF in 73 patients, using CMR imaging as a reference. Protocol 1: 10 patients were compared by two examiners using the biplane disk summation method with trace line based on the empirical judgment of the examiner (before-learning) and trace line along the inner side of the high-intensity echo band (after-learning), and inter- and intra-observer variabilities were calculated. Protocol 2: the accuracy of LV volumes and EF was compared in 73 patients using the after-learning method. Bland-Altman analysis were used to compare with 2DE and CMR. The coefficient of variation was used for inter- and intra-observer variabilities.</p><p><strong>Results: </strong>Protocol 1: For examiner 1, EDV (-16 ml vs 1 ml, p = 0.001), ESV (-9 ml vs 1 ml, p = 0.004), and SV (-7 ml vs 0 ml, p = 0.037) after learning compared with before learning were significantly approximated CMR measurements. For examiner 2, no significant differences were noted between before and after learning. The variability in measurements was smaller for all items by both examiners. Inter-observer variability after learning was improved compared with before learning, and intra-observer variability was also better. Protocol 2: LV volumes and EF measurements after learning were almost as accurate as CMR.</p><p><strong>Conclusions: </strong>LV volumes and EF using after-learning trace approximated CMR measurements. Having landmark on trace line may contribute to quality control.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world safety of sacubitril/valsartan in Japanese patients with chronic heart failure: A post-marketing surveillance study.","authors":"Jiro Arita, Tomomi Ohishi, Takayoshi Sasajima, Daisuke Yarimizu, Katsuya Onishi","doi":"10.1016/j.jjcc.2025.05.020","DOIUrl":"10.1016/j.jjcc.2025.05.020","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the safety of sacubitril/valsartan for up to 52 weeks in Japanese patients with chronic heart failure (CHF) in real-world settings.</p><p><strong>Methods: </strong>This was an uncontrolled, multicenter, observational study conducted at 120 sites in Japan. Adult patients on standard of care for CHF and newly initiated on sacubitril/valsartan were included. The primary outcome was the exposure-adjusted incidence rate (EAIR: patients/100 patient-years) of adverse drug reactions (ADRs) and adverse events of interest (related to hypotension, hyperkalemia, renal impairment, and dehydration). The impact of patient risk factors on ADRs and clinical outcomes (EAIR of the composite endpoint [cardiovascular (CV) death or first hospitalization due to heart failure], and its components) were also assessed.</p><p><strong>Results: </strong>Overall, 682 patients (median age: 78.0 years, male: 61.4 %, age 75 years: 61.9 %) were assessed. Sacubitril/valsartan was typically initiated at 50 mg twice daily and up-titrated to 100 mg or 200 mg sequentially at 2- to 4-week intervals. Dose adjustments were made in 57.2 % of patients. EAIRs of ADRs related to hypotension, hyperkalemia, renal impairment, and dehydration were 7.776, 0.606, 0.913, and 0.151, respectively. The incidence of ADRs was 9.7 %, with hypotension (4.7 %) and decreased blood pressure (1.8 %) being the most common ADRs. Patients with systolic blood pressure (SBP) of ≤120 mmHg at sacubitril/valsartan initiation had a higher risk of ADRs than those in other SBP groups. EAIRs for composite endpoints, CV death, and first hospitalization for heart failure were 9.404, 2.269, and 8.150, respectively.</p><p><strong>Conclusions: </strong>This study did not show notable differences from the known safety profile of sacubitril/valsartan, and no new safety concerns were identified in Japanese patients with CHF. The EAIR of the composite endpoint of CV death or first hospitalization due to heart failure was lower than that in patients enrolled in clinical studies at the time of approval.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery calcification as an incremental predictive risk: Research perspectives in primary prevention","authors":"Alberto Cereda MD ,&nbsp;Antonio G. Franchina MD ,&nbsp;Lorenzo Tua MD ,&nbsp;Matteo Rocchetti MD ,&nbsp;Davide Garattini MD ,&nbsp;Emilia D'Elia PhD ,&nbsp;Stefano Lucreziotti MD","doi":"10.1016/j.jjcc.2024.12.005","DOIUrl":"10.1016/j.jjcc.2024.12.005","url":null,"abstract":"<div><div>Coronary artery calcium (CAC) score is a neglected biomarker that can be derived from non-cardiac chest computed tomography scan and represents a surrogate for atherosclerosis. We created a simulation model using different CAC score values in the MESA coronary artery risk score in a population derived from the Fourier Trial. CAC score could modulate the sample sizes of cardiovascular trials in primary and secondary prevention and offer new primary prevention treatments to high-risk subjects with reasonable numbers needed to treat comparable to secondary prevention trials.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 502-504"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JCS/JCC/JACR/JATS 2024 guideline on cardiovascular practice with consideration for diversity, equity, and inclusion","authors":"Yayoi Tetsuou Tsukada,&nbsp;Chizuko Aoki-Kamiya,&nbsp;Atsushi Mizuno,&nbsp;Atsuko Nakayama,&nbsp;Tomomi Ide,&nbsp;Rie Aoyama,&nbsp;Junko Honye,&nbsp;Katsuyuki Hoshina,&nbsp;Toshimi Ikegame,&nbsp;Koki Inoue,&nbsp;Yasuko K. Bando,&nbsp;Masaharu Kataoka,&nbsp;Naoki Kondo,&nbsp;Koji Maemura,&nbsp;Miyuki Makaya,&nbsp;Naoya Masumori,&nbsp;Asako Mito,&nbsp;Mizuho Miyauchi,&nbsp;Aya Miyazaki,&nbsp;Yukiko Nakano,&nbsp;Hitonobu Tomoike","doi":"10.1016/j.jjcc.2025.03.002","DOIUrl":"10.1016/j.jjcc.2025.03.002","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 510-574"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial differences in diuretic therapy, B-type natriuretic peptide values, and prognosis in acute heart failure","authors":"Yu Horiuchi ,&nbsp;Yuya Matsue MD, PhD ,&nbsp;Nicholas Wettersten ,&nbsp;Shogo Oishi ,&nbsp;Eiichi Akiyama ,&nbsp;Satoshi Suzuki ,&nbsp;Masayoshi Yamamoto ,&nbsp;Keisuke Kida ,&nbsp;Takahiro Okumura ,&nbsp;Takeshi Kitai ,&nbsp;Dirk J. van Veldhuisen ,&nbsp;Alan Maisel ,&nbsp;Patrick T. Murray ,&nbsp;Tohru Minamino","doi":"10.1016/j.jjcc.2025.01.013","DOIUrl":"10.1016/j.jjcc.2025.01.013","url":null,"abstract":"<div><h3>Background</h3><div>Whether variability of B-type natriuretic peptide (BNP) values between races affects its clinical integration as a marker for congestion and predictor of prognosis in acute heart failure (AHF) remains unknown. We aimed to investigate the relationship between diuretic therapy, change in BNP value, and prognosis in AHF in relation to racial differences.</div></div><div><h3>Methods</h3><div>This analysis combined data from the AKINESIS and REALITY-AHF studies. We included White, Black, and Asian individuals admitted with AHF requiring intravenous diuretic therapy. We examined the relative change in BNP values at 48 h post hospital admission, and its association with diuretic therapy and one-year mortality.</div></div><div><h3>Results</h3><div>Of 1380 participants, 29 % were White, 12 % were Black, and 58 % were Asian. Admission BNP values were highest in Black, followed by Asian and White individuals. After adjusting for confounding factors, Black individuals had significantly higher admission BNP values compared to White individuals. During the first 48 h of hospitalization, Asian individuals received the lowest diuretic dose but demonstrated the greatest diuretic response and BNP decrease. After adjustment for confounding factors, Asian individuals were more likely to have a BNP decrease compared to White individuals. Higher admission BNP values predicted higher one-year mortality in White and Asian but not in Black individuals (<em>p</em> for interaction = 0.021). BNP decrease was associated with a lower one-year mortality without a significant interaction by race.</div></div><div><h3>Conclusions</h3><div>In AHF patients, admission BNP was higher in Black, and its decrease after diuretic therapy was greater in Asian individuals. A BNP decrease predicted a better prognosis, regardless of race.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 486-493"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-echocardiography: Current status and future direction","authors":"Yuki Sahashi MD, MSc ,&nbsp;David Ouyang MD ,&nbsp;Hiroyuki Okura MD, PhD, FJCC ,&nbsp;Nobuyuki Kagiyama MD, PhD","doi":"10.1016/j.jjcc.2025.02.005","DOIUrl":"10.1016/j.jjcc.2025.02.005","url":null,"abstract":"<div><div>Echocardiography, which provides detailed evaluations of cardiac structure and pathology, is central to cardiac imaging. Traditionally, the assessment of disease severity, treatment effectiveness, and prognosis prediction relied on detailed parameters obtained by trained sonographers and the expertise of specialists, which can limit access and availability. Recent advancements in deep learning and large-scale computing have enabled the automatic acquisition of parameters in a short time using vast amounts of historical training data. These technologies have been shown to predict the presence of diseases and future cardiovascular events with or without relying on quantitative parameters. Additionally, with the advent of large-scale language models, zero-shot prediction that does not require human labeling and automatic echocardiography report generation are also expected. The field of AI-enhanced echocardiography is poised for further development, with the potential for more widespread use in routine clinical practice. This review discusses the capabilities of deep learning models developed using echocardiography, their limitations, current applications, and research utilizing generative artificial intelligence technologies.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 458-464"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaboration between dyspnea clinic and primary care physicians to identify heart failure with preserved ejection fraction in the community: Results from the Maebashi City HF project","authors":"Naoki Yuasa MD ,&nbsp;Satoshi Ubukata MD ,&nbsp;Ryo Takayanagi MD ,&nbsp;Eiji Yamashita MD ,&nbsp;Keiji Hoshino MD ,&nbsp;Yuta Tani MSc ,&nbsp;Takashi Kawashima MD, PhD ,&nbsp;Hideki Ishii MD, PhD, FJCC ,&nbsp;Masaru Obokata MD, PhD","doi":"10.1016/j.jjcc.2025.01.001","DOIUrl":"10.1016/j.jjcc.2025.01.001","url":null,"abstract":"<div><h3>Background</h3><div>Despite increasing awareness in general practice, heart failure with preserved ejection fraction (HFpEF) remains under-diagnosed in the community due to diagnostic difficulties. Dedicated dyspnea clinics are responsible for diagnosing HFpEF and efficient referral from primary care physicians is the key to enhance its role.</div></div><div><h3>Methods</h3><div>This retrospective analysis was performed to assess the effectiveness of a one-year collaborative project between our dyspnea clinic and the Maebashi Medical Association. Primary care physicians were encouraged to screen patients at risk for HFpEF and refer them to the dyspnea clinic, where exercise stress echocardiography was utilized to enhance the identification of HFpEF. To evaluate the clinical value of the project, the data obtained were compared with data from the previous year without collaboration.</div></div><div><h3>Results</h3><div>The collaborative project was conducted between May 2023 and May 2024. The rate of patients referred from the city increased from 47 % during the previous year to 87 % during the collaborative period (<em>p</em> &lt; 0.0001). Most of the patients were referred by non-cardiologists (77 %). The prevalence of HFpEF diagnosis tended to increase from 32 % to 39 % after the collaborative project, while pulmonary causes of dyspnea tended to decrease from 21 % to 12 %. After a thorough evaluation at the dyspnea clinic, 98 % of referred patients were referred back to their referring physicians for further treatment and follow-up.</div></div><div><h3>Conclusions</h3><div>These data suggest the effectiveness of our approach to identify HFpEF in the community through collaboration between the dedicated dyspnea clinic and primary care physicians.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 480-485"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairment in patients with heart failure: Physiopathology, clinical implications, and therapeutic considerations","authors":"Meng Li MD, PhD ,&nbsp;Junping Zhang MD, PhD ,&nbsp;Yue Hu MD, PhD ,&nbsp;Yue Zhang MM","doi":"10.1016/j.jjcc.2025.02.007","DOIUrl":"10.1016/j.jjcc.2025.02.007","url":null,"abstract":"<div><div>Cognitive impairment (CI) is a significant comorbidity in individuals with heart failure (HF). A substantial number of patients with HF may experience CI, which can present as deficits in attention, memory, executive function, and processing speed. HF patients with CI tend to have reduced functional independence, self-care capabilities, medication adherence and decision-making ability, along with more frequent rehospitalizations, and an increased risk of mortality. Currently, there is no established gold standard diagnostic tool or follow-up strategy for assessing CI in patients with HF. There has been an increasing recognition of the complex bidirectional relationship between HF and CI. However, the exact pathological mechanisms of CI in HF need further in-depth investigation. This review aims to explore the current epidemiological status of CI in patients with HF, the relationship between HF and cognitive dysfunction, the pathological mechanisms involved, as well as the early screening, diagnosis, and management issues for HF patients with CI. It also discusses prevention and intervention strategies. The objective is to provide a scientific basis for the clinical diagnosis, management, and treatment of CI in HF, while proposing future research directions to advance this field.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 6","pages":"Pages 465-472"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}